Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Jupiter Neurosciences (JUNS) Stock Forecast & Price Target

Jupiter Neurosciences logo
Get the Latest News and Ratings for JUNS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Jupiter Neurosciences and its competitors.

Sign Up

JUNS Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
1 Strong Buy rating(s)
N/A N/A N/A
Buy
0 Buy rating(s)
N/A N/A N/A
Hold
0 Hold rating(s)
N/A N/A N/A
Sell
0 Sell rating(s)
N/A N/A N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus Rating
Strong Buy
N/AN/AN/A

JUNS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JUNS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Jupiter Neurosciences Stock vs. The Competition

TypeJupiter NeurosciencesMedical CompaniesS&P 500
Consensus Rating Score
4.00
2.81
2.51
Consensus RatingStrong BuyModerate BuyModerate Buy
Predicted UpsideN/A25,828.59% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent JUNS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/19/2024Greenridge Global
1 of 5 stars
W. Gregozeski
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:25 AM ET.


JUNS Forecast - Frequently Asked Questions

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jupiter Neurosciences in the last year. There is currently 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "strong buy" JUNS shares.

According to analysts, Jupiter Neurosciences's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Jupiter Neurosciences's stock had 1 upgrade by analysts.

Jupiter Neurosciences has been rated by research analysts at Greenridge Global in the past 90 days.

Analysts like Jupiter Neurosciences more than other "medical" companies. The consensus rating for Jupiter Neurosciences is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how JUNS compares to other companies.


This page (NASDAQ:JUNS) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners